267228-40-0

Upstream product

• 64-17-5 ethanol 
• 162919-37-1 (S)-3-[4-(benzyloxy)phenyl]-2-hydroxypropanoic acid 
• 156-39-8 4-hydroxyphenylpiruvic acid 
• 23508-35-2 (S)-2-hydroxy-3-(4-hydroxy-phenyl)-propionic acid 
• 100-44-7 benzyl chloride 

Downstream Products

• 251454-50-9 ethyl (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoate 
• 1416820-82-0 (2S)-2-ethoxy-3-{4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}propanoic acid 
• 1416820-81-9 ethyl (2S)-2-ethoxy-3-{4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}propanoate 
• 267228-41-1 latifolicinin B 
• 222555-06-8 ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 481072-39-3 3-(4-benzyloxy-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-propionic acid ethyl ester 

Relevant academic research and scientific papers

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic β-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPARα, PPARγ and PPARβ/(δ). We were interested in designing novel PPARγ selective agonists and/or dual PPARα/γ agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail.

Synthesis of a peroxime proliferator activated receptor (PPAR) α/γ agonist via stereocontrolled Williamson ether synthesis and stereospecific SN2 reaction of S-2-chloro propionic acid with phenoxides

The stereospecific synthesis of the PPAR α/γ agonist 1 was accomplished via ethylation of the optically pure trihydroxy derivative 6, itself derived via an enzymatic resolution. The ethylation can be accomplished without epimerization only under strict control of the reaction conditions and the choice of base (sodium tert-amylate), temperature (-30°C), order of addition, and solvent (DMF). The key diastereospecific SN2 reaction of the phenol 4 with S-2-chloropropionic acid is best achieved via the sodium phenoxide of 4 derived from Na0 as the reagent of choice. The structure elucidation and key purification protocols to achieve pharmaceutical purity will also be described

PROCESS FOR PREPARING 3-ARYL-2-HYDROXY PROPANOIC ACID DERIVATIVES WITHOUT RESOLUTION

The present invention discloses an improve process for the preparation of S (-) and R (+) 3-aryl-2-hydroxy propanoic acid derivatives without any resolution involved.

Process for the preparation of new antidiabetic agents

The present invention relates to an improved process for the preparation of novel antidiabetic compounds having formula (1) where R1represents hydrogen or lower alkyl group and X represents hydrogen or halogen atom.